ADC Therapeutics (ADCT) is down -4.6%, or -15c to $3.11.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADCT:
- ADC Therapeutics announces new data from Phase 2 trial of Zynlonta
- ADC Therapeutics price target raised to $10 from $7 at Guggenheim
- ADC Therapeutics Announces $100M Private Placement
- ADC Therapeutics to sell 13M shares at $3.53 in private placement
- ADC Therapeutics announces updated data from LOTIS-7 trial